RxDoctor Payments Data

Victoria Barkley

Acute Care · Sioux City, IANPI 1134875172

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Abiomed at 44.4% of the total. Reporting peaked in 2022 at $204 and has fallen 92.6% since, to $15 in 2025. That places this record below the midpoint for acute care clinicians in IA, where the typical reported total is $313.

$358in general payments, 2019–2025

Across 17 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$159
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$51
  • AstraZeneca$39
  • Amgen$25
  • Medtronic$21
  • Livanova USA, Inc.$19
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$358100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$358 in reported general payments places this provider in the 50th percentile of 104 acute care providers in Iowa.

See all acute care providers in Iowa

Medicare billing

Part B allowed, 2024
$35,167
Medicare patients
315
Services billed
556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$48,376
EntrestoSacubitril/Valsartan45$37,721
FarxigaDapagliflozin Propanediol42$34,414
BrilintaTicagrelor51$23,312
Metoprolol Succinate104$1,160
ClopidogrelClopidogrel Bisulfate233$1,025
Isosorbide Mononitrate ErIsosorbide Mononitrate64$608
Bumetanide17$583
Atorvastatin Calcium139$579
Pantoprazole Sodium40$495
Colchicine21$434
Potassium Chloride23$365
Ranolazine ErRanolazine11$359
Nitroglycerin26$207
Amiodarone Hcl15$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$39$57,72693 claims
PfizerEliquis$15$48,37677 claims
NovartisEntresto$15$37,72145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 104 acute care providers in Iowa.

Other acute care in Sioux City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →